-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 13, LENZ Therapeutics (hereinafter referred to as LENZ) and Keixing Pharmaceutical announced that the two parties have signed an exclusive license for the development and commercialization of the drugs LNZ100 and LNZ101 developed by the former for the treatment of presbyopia in Greater China.
Presbyopia (also known as presbyopia) is a progressive and irreversible decline in the eye's ability to focus on near objects due to the hardening of the lens in the eye with age
Acetylcridine is a small-molecule acetylcholinesterase receptor agonist that causes pupillary miosis, resulting in a pinhole effect that improves near vision
A clinical trial completed by LENZ showed that acetylcridine maintained optimal pin pupil size ranging from 1.
Note: The original text has been deleted